| 引用本文: |
黄刚,罗海恩,苏新平,谭旭仪,何灿宇,李小东,张道伟.止痛健骨方对原发性骨质疏松症患者骨密度及OPG、RANKL的影响及疗效观察[J].湖南中医药大学学报,2020,40(12):1544-1547[点击复制] |
|
| |
|
|
| 本文已被：浏览 2433次 下载 1276次 |
| 止痛健骨方对原发性骨质疏松症患者骨密度及OPG、RANKL的影响及疗效观察 |
| 黄刚,罗海恩,苏新平,谭旭仪,何灿宇,李小东,张道伟 |
| (湖南省中医药研究院附属医院, 湖南 长沙 410006;湖南中医药大学, 湖南 长沙 410208) |
| 摘要: |
| 目的 观察止痛健骨方对原发性骨质疏松症（osteoprotegerin，OP）患者骨密度（bone mineral density，BMD）及骨保护蛋白（osteoprotegerin，OPG）、核因子-κβ受体活化因子配体（receptor activator of nuclear factor-κβ ligand，RANKL）的影响及疗效，探讨其治疗OP的作用机制。方法 将原发性OP患者70例按入组顺序随机分为对照组和治疗组，各35例。两组均给予依降钙素、钙尔奇D等基础治疗，治疗组加服止痛健骨方煎剂，分别于治疗前、治疗8周后评价两组患者临床疗效，观察比较两组患者BMD、疼痛视觉模拟评分（visual analogue score，VAS）及血清OPG、RANKL的表达。结果 治疗8周后，治疗组在改善症状方面明显优于对照组（P<0.05），BMD、血清OPG高于治疗前及对照组（P<0.05），VAS评分、血清RANKL低于治疗前及对照组（P<0.05）。结论 止痛健骨方可有效提高OP患者OPG表达、降低RANKL表达，以达到增加患者BMD及改善症状的作用，这可能是其治疗原发性OP的作用机制之一。 |
| 关键词: 原发性骨质疏松症 止痛健骨方 骨密度 骨保护蛋白 核因子-κβ受体活化因子配体 |
| DOI：10.3969/j.issn.1674-070X.2020.12.020 |
| 投稿时间：2020-02-21 |
| 基金项目:湖南省中医药管理局重点课题（201908）。 |
|
| Observation on Effects and Efficacy of Zhitong Jiangu Decoction on Bone Mineral Density, OPG and RANKL in Patients with Primary Osteoporosis |
| HUANG Gang,LUO Haien,SU Xinping,TAN Xuyi,HE Canyu,LI Xiaodong,ZHANG Daowei |
| (The Affiliated Hospital of Hunan Academy of Traditional Chinese Medicine, Changsha, Hunan 410006, China;Hunan University of Chinese Medicine, Changsha, Hunan 410208, China) |
| Abstract: |
| Objective To observe effects and efficacy of Zhitong Jiangu Decoction on bone mineral density (BMD), osteoprotegerin (OPG) and receptor activator of nuclear factor-κβ ligand (RANKL) in patients with primary osteoporosis (OP), and to explore its mechanism of action in treating OP. Methods A total of 70 patients with primary OP were randomly assigned into a control group and a treatment group according to the order of enrollment, with 35 patients in each group. Both groups were given basic treatment with Elcatonin and Caltrate D, and the treatment group was also given Zhitong Jiangu Decoction. Clinical efficacy in the 2 groups was evaluated before the treatment and after 8 weeks of the treatment, and BMD, visual analogue scores (VAS) and expressions of serum OPG and RANKL in the 2 groups were observed and compared. Results After 8 weeks of the treatment, the treatment group was significantly better than the control group in improving symptoms (P<0.05), the BMD and the serum OPG were higher than those before the treatment and those in the control group (P<0.05), and the VAS score and the serum RANKL were lower than those before the treatment and those in the control group (P<0.05). Conclusion Zhitong Jiangu Decoction can effectively increase the OPG expression and decrease the RANKL expression in OP patients, so as to increase BMD and improve symptoms in the patients. This may be one of its mechanisms of action in treating primary OP. |
| Key words: primary osteoporosis Zhitong JianGu Decoction bone mineral density osteoprotegerin receptor activator of nuclear factor-κβ ligand |
|
二维码（扫一下试试看！） |
|
|
|
|
